How Hedge Funds Use FOIA to Stay Ahead of the Market
FOIAengine: Warning Letters and Inspection Reports in the Spotlight
By John A. Jenkins, Law St. Media, Jan. 14, 2026
Freedom of Information Act requests filed with the Food and Drug Administration by hedge funds last month revealed big financial players closely eyeing warning letters, enforcement documents, and inspection reports for major drug manufacturers and biopharma companies.
At the forefront was a sweeping request from Greenwich, Conn.-based Deep Track Capital for all Form 483 inspection reports issued by the FDA over nearly three years to two companies – CG Oncology (NASDAQ: CGON), which develops immunotherapies for bladder cancer; and Biovire, a contract manufacturer specializing in the final step of packaging “novel drugs and medical devices” for patient use.
Deep Track, focused exclusively on the life sciences industry, has $5.2 billion in assets under management and invests in public and pre-IPO biotechnology companies. Form 483 reports, which the hedge fund is seeking, describe plant-inspection observations made by the FDA.
Read more here.